Viral Immunology, Vaccines, and Antivirals
A section of Viruses (ISSN 1999-4915).
Section Information
- acquired resistance and evolution
- regulatory/societal/legislation aspects
- immune system stimulation
- limitations of vaccines
- new developments and the future
- natural antivirals and their uses
- viral infections
- differences between antivirals and antibiotics in health care
- antiviral use in children
- immunology/animal models
- adverse effects
Editorial Board
Topical Advisory Panel
Special Issues
Following special issues within this section are currently open for submissions:
- The Diverse Regulation of Transcription in Endogenous Retroviruses (Deadline: 31 August 2024)
- Host Cell-Virus Interaction, 3rd Edition (Deadline: 31 August 2024)
- Mechanisms of Herpesvirus Resistance (Deadline: 31 August 2024)
- Viruses, MicroRNAs and Host Interactions (Deadline: 31 August 2024)
- Antibody Response to Dengue, Zika and Other Flaviviruses (Deadline: 31 August 2024)
- Antiviral Resistance Mutations (Deadline: 31 August 2024)
- Chronic Infection by Oncogenic Viruses (Deadline: 15 September 2024)
- Viral Sepsis: Pathogenesis, Diagnostics and Therapeutics (Deadline: 15 September 2024)
- Antiviral Molecular Mechanisms - Second Edition (Deadline: 30 September 2024)
- Antibody Cross-Reactivity in Virus Infection (Deadline: 30 September 2024)
- CRISPR/Cas in Viral Research 2024 (Deadline: 30 September 2024)
- Immunity to Enteric Viruses (Deadline: 30 September 2024)
- Regulation of the Virus Lifecycle by Cellular RNA-Binding Proteins (Deadline: 30 September 2024)
- Advanced Strategies against SARS-CoV-2 Variants and Future Emerging Virus Outbreaks (Deadline: 15 October 2024)
- HIV Protease (Deadline: 30 October 2024)
- Pharmacology of Antiviral Drugs (Deadline: 31 October 2024)
- Pharmacology of HIV Treatment and Antivirals against Hepatitis Viruses (Deadline: 31 October 2024)
- Novel and Repurposed Antiviral Agents, 2nd Edition (Deadline: 31 October 2024)
- Influenza, SARS-CoV-2, RSV and Other Vaccines: Immunogenicity Parameters and Protection, 3rd Edition (Deadline: 31 October 2024)
- The Challenge of HIV Diversity (Deadline: 31 October 2024)
- Natural Killer Cell in Viral Infection (Deadline: 31 October 2024)
- Antiviral Drugs and Biologics Targeting HIV: Drug Resistance to Newer Treatment and Pre-Exposure Prophylaxis (PrEP) Options (Deadline: 31 October 2024)
- Antiviral Immune Responses of Bat (Deadline: 31 October 2024)
- The Role of Dendritic Cells and Macrophages in HIV Infection (Deadline: 15 November 2024)
- Recent Advances in Anti-HCV, Anti-HBV and Anti-flavivirus Agents (Deadline: 15 November 2024)
- Viral Infections and Immune Dysregulation 2023 (Deadline: 25 November 2024)
- Unraveling the Pathogenesis of Persistent Virus Infection (Deadline: 30 November 2024)
- Emerging and Re-emerging Zoonotic Viruses: Current Challenges in Vaccinology (Deadline: 30 November 2024)
- The Inflammasomes - Key Players in Antiviral Response (Deadline: 30 November 2024)
- How to Adjust the Action Steps for Achieving the Global Hepatitis Virus (HBV/HCV/HDV) Elimination Targets? (Deadline: 30 November 2024)
- Viral Replication Inhibitors (Deadline: 30 November 2024)
- Role of Lectins in Viral Infections and Antiviral Intervention (Deadline: 30 November 2024)
- Viral Resistance (Deadline: 31 December 2024)
- Viruses and Virus-Like Particles as Nanoplatforms for Vaccines, Diagnostic and Therapeutic Nanomedicine (Deadline: 31 December 2024)
- Elimination of Viral Hepatitis: Improving Diagnosis, Treatment and Surveillance 2.0 (Deadline: 31 December 2024)
- Chemokines and Chemokine Receptors in Viral Infection 2024 (Deadline: 31 December 2024)
- Epigenetic and Transcriptional Regulation of DNA Virus Infections (Deadline: 31 December 2024)
- Conquering Antiviral Drug Resistance via Development of Novel Antivirals and New Testing Methods for Drug Resistance: From Bench to Bedside (Deadline: 31 December 2024)
- Novel Antiviral Agents: Synthesis, Molecular Modelling Studies and Biological Investigation, 2nd Edition (Deadline: 31 December 2024)
- Innate and Adaptive Immune Responses to Arbovirus Infections (Deadline: 15 January 2025)
- Antiviral Agents to Influenza Virus 2024 (Deadline: 31 January 2025)
- Interferon Signaling in Viral Pathogenesis (Deadline: 31 January 2025)
- Virus-Host Protein Interactions (Deadline: 31 January 2025)
- B Cell-Mediated Immunity to Viruses (Deadline: 19 February 2025)
- Virology and Immunology of Gene Therapy (Deadline: 28 February 2025)
- Host-Directed Antiviral Therapy (Deadline: 15 March 2025)
- Broad-Spectrum Antivirals and Interaction with Viruses: 2nd Edition (Deadline: 31 March 2025)
- Universal Influenza Vaccines for Humans and Animals (Deadline: 31 March 2025)
- Advancements in Immunotherapy for Human Papillomavirus (Deadline: 30 April 2025)
- Nanovaccines against Viral Infection (Deadline: 30 April 2025)
- Natural, Semisynthetic, and Synthetic Antiviral Drugs Targeting HIV and SARS-CoV-2 (Deadline: 31 August 2025)
Topical Collection
Following topical collection within this section is currently open for submissions: